Completed PHASE3 INTERVENTIONAL 3-arm NCT01079234

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes (BEGIN™)

A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)

Sponsor: Novo Nordisk A/S

Conditions Diabetes Diabetes Mellitus, Type 1

Interventions insulin aspart insulin degludec insulin glargine

Updated 7 times since 2017 Last updated: Dec 16, 2016 Started: Mar 31, 2010 Primary completion: Nov 30, 2010 Completion: May 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01079234, this PHASE3 trial focuses on Diabetes and Diabetes Mellitus, Type 1 and remains completed. Sponsored by Novo Nordisk A/S, it has been updated 7 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalst, Belgium , Arlington, United States , Arlon, Belgium , Asheville, United States , Athens, Greece , Aurora, United States , Bad Kreuznach, Germany , Baltimore, United States , Belfast, United Kingdom , Bergen, Norway and 64 more locations